Skip to main content

When Noel Hall and two colleagues established Aspreva Pharmaceuticals Corp. in Victoria six years ago, their concept was revolutionary: Make money by finding existing drugs that - in addition to treating a specific disease - can also help with other, less common medical problems.

The company hit the jackpot in 2003 when it signed a licensing deal with Roche AG for the drug CellCept, a product used to fight rejection after organ transplants, but which also helps treat auto-immune diseases such as Lupus.

Aspreva got to keep a portion of all CellCept sales made for non-transplant uses, in return for doing development work and running clinical trials to study how the drug functions in these other applications.

Story continues below advertisement

In 2005, Aspreva went public in a $113-million (Canadian) public offering at $13.68 a share. Yesterday, initial investors almost doubled their money as the company revealed it is being sold for a whopping $915-million (U.S.) or $26 a share to Swiss biotech giant Galenica Group.

The company has been breaking ground all through its history, said Mr. Hall, who is now president of Aspreva. "We were founded on a breakthrough business development [concept]that nobody had ever thought of," he said. "And nobody ever thought we could pull off the sort of deal we pulled off with Roche."

Mr. Hall, along with co-founders Richard Glickman and Michael Hayden, all had years of experience in the biotech business, but they had trouble getting initial financing for Aspreva.

"Nobody really believed us and the Canadian venture capital community shunned us," he said. "It was a classic startup where we had to finance the company ourselves supported by some great angel investors who really believed in us."

The Galenica transaction came about because Aspreva has been scouring the globe trying to find another drug partner to follow up on its deal with Roche.

Galenica, whose activities range from drug development to running pharmacies, had products in its pipeline that looked like they might glean new markets through a relationship with Aspreva.

As talks progressed, a joint venture was considered, then a takeover was proposed.

Story continues below advertisement

"They became so compelled by what Aspreva could do for their assets, that they made an unsolicited friendly offer," Mr. Hall said.

Rather than disappointment among employees that the company is shifting into other hands, "there's a real sense of excitement and buzz, because they're getting to be part of the next chapter," he said. "There is a sense we're building the next phase of our company."

After Galenica made its takeover bid, Aspreva did a "limited" check of other possible scenarios "to make sure we weren't missing something," chief executive officer William Freytag said on a conference call with analysts yesterday, but it found no better scenario on the horizon.

Mr. Freytag, who joined the company in July to succeed Mr. Glickman as chairman and CEO, said completing the deal with Galenica was a "classic bittersweet scenario."

In a short time "I've basically fallen in love with this company," he said, but the deal with Galenica "clearly represented a very significant opportunity for our shareholders."

Directors, managers and the company's largest shareholder have signed lock-up agreements with Galenica covering about 30 per cent of Aspreva's common shares. Shareholders will vote on the deal in December - two-thirds must agree for it to go through - and the sale is expected to close in early January.

Story continues below advertisement

Brian Bapty, an analyst at Raymond James in Vancouver, said the Galenica offer looks like a "good price," and he expects the deal to close without any other bidders surfacing.

Aspreva will bring Galenica a strong marketing organization, and skills in running clinical studies, Mr. Bapty said. "The buyer gets an instant global footprint and substantially increases its ability to market drugs."

Aspreva (ASPV)

Close: $25.61, up $3.11

Report an error Editorial code of conduct
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

Cannabis pro newsletter
To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies